Hims & Hers Health Inc. (NYSE:HIMS) price is hovering higher on Monday, September 13, jumping 1.86% above its previous close.
A look at today’s price movement shows that the recent level at last check reads $8.87, with intraday deals fluctuating between $8.54 and $9.105. Taking into account the 52-week price action we note that the stock hit a 52-week high of $25.40 and 52-week low of $6.71. The stock added 5.72% on its value in the past month.
Hims & Hers Health Inc., which has a market valuation of $1.80 billion, is expected to release its quarterly earnings report Aug 11, 2021. Analysts tracking HIMS have forecast the quarterly EPS to shrink by -0.06 per share this quarter, while the same analysts predict the annual EPS to hit -$0.37 for the year 2021 and up to -$0.16 for 2022. In this case, analysts estimate an annual EPS growth of -60.90% for the year and 56.80% for the next year.
On average, analysts have forecast the company’s revenue for the quarter will hit $70.53 million, with the likely lows of $70.1 million and highs of $71.16 million. Staying with the analyst view, there is a consensus estimate of $253.89 million for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to grow 70.70% above that which the company brought in 2021.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give HIMS a short term outlook of 50% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 4 analysts have assigned HIMS a recommendation rating as follows: 2 rate it as a Hold; 2 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Hims & Hers Health Inc. (HIMS) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Overweight, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that HIMS’s price is at present 14.57% off the SMA20 and 6.48% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 59.69, with weekly volatility standing at 7.92%. The indicator jumps to 7.51% when calculated based on the past 30 days. Hims & Hers Health Inc. (NYSE:HIMS)’s beta value is holding at 0, while the average true range (ATR) indicator is currently reading 0.60. Considering analysts have assigned the stock a price target range of $10.00-$14.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $11.75. Based on this estimate, we see that today’s price at last check is roughly -10.74% off the estimated low and -55.04% off the forecast high. Investors will no doubt be excited to see the share price fall to $11.50, which is the median consensus price, and at that level HIMS would be -27.35% from recent price.
An analysis of the Hims & Hers Health Inc. (NYSE:HIMS) stock in terms of its daily trading volume indicates that the 3-month average is 2.45 million.
Current records show that the company has 191.92M in outstanding shares. The insiders’ percentage holdings are 1.00% of outstanding shares while the percentage share held by institutions stands at 56.40%. But the -39.25% downside, the stock’s price has registered year-to-date as of today’s value, will likely reignite investor interest given the prospect of it rallying even higher.